Analyst Expectations for Cerevel Therapeutics Hldg's Future
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 10 analysts have published their opinion on Cerevel Therapeutics Hldg (NASDAQ:CERE) stock, with an average 12-month price target of $32.6, a 12.58% decrease from the previous average price target of $37.29.
May 23, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cerevel Therapeutics Hldg (NASDAQ:CERE) has an average 12-month price target of $32.6, a 12.58% decrease from the previous average price target of $37.29, based on the opinions of 10 analysts.
The article provides an overview of the opinions of 10 analysts on Cerevel Therapeutics Hldg (NASDAQ:CERE) stock. The average 12-month price target has decreased by 12.58% to $32.6, which may indicate a change in sentiment among analysts. However, the overall sentiment remains mixed, with 2 bullish, 2 somewhat bullish, and 6 indifferent ratings. This suggests that the stock's short-term price direction is uncertain, and the impact on the stock price is neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100